Virus-like particles (VLPs) are increasingly used for vaccine development and drug delivery.
Assembly of VLPs from purified monomers in a chemically defined reaction is advantageous …

Small molecules that bind to the viral capsid protein can be potent inhibitors of HIV infection.
Capsid-targeting drugs are predicted to exhibit high barriers to viral resistance, and ongoing …

The HIV-1 capsid is a fullerene cone made of quasi-equivalent hexamers and pentamers of
the viral CA protein. Typically, quasi-equivalent assembly of viral capsid subunits is …

Human immunodeficiency virus type 1 (HIV-1) infection depends on efficient
intracytoplasmic transport of the incoming viral core to the target cell nucleus. Evidence …

The human immunodeficiency virus type 1 (HIV-1) capsid plays crucial roles in HIV-1
replication and thus represents an excellent drug target. We developed a high-throughput …

Considerable success has been achieved in the treatment of HIV-1 infection, and more than
two-dozen antiretroviral drugs are available targeting several distinct steps in the viral …

The human immunodeficiency virus type 1 capsid is modeled as a fullerene cone that is
composed of∼ 250 hexamers and 12 pentamers of the viral CA protein. Structures of CA …

The human immunodeficiency virus type 1 (HIV-1) matrix (MA) protein targets HIV-1
precursor Gag (PrGag) proteins to assembly sites at plasma membrane (PM) sites that are …

Background: The infectious human immunodeficiency virus (HIV) particle is characterized by
a conical capsid that encloses the viral RNA genome. The capsid is essential for HIV-1 …

The matrix (MA) domains of HIV-1 precursor Gag (PrGag) proteins direct PrGag proteins to
plasma membrane (PM) assembly sites where envelope (Env) protein trimers are …